PDCD1 and melanoma: For example, the advent of immune checkpoint inhibition by antibodies against the programmed cell death protein 1 (PD1; pembrolizumab and nivolumab) or the cytotoxic T lymphocyte antigen 4 (CTLA-4; ipilimumab) resulted in an outcome improvement of patients with melanoma brain metastases.